Investors

Webcast ImageWebcast
Q2 2016 Edge Therapeutics, Inc. Earnings Conference Call (Replay)
August 3, 2016 at 8:30 a.m. ET
Q2 2016 Edge Therapeutics, Inc. Earnings Conference Call
Wednesday, August 3, 2016 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More

Lastest News

August 3, 2016 - Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights
Read More
August 2, 2016 - Edge Therapeutics Announces Closing of $20 Million Debt Facility with Hercules Capital, Inc.
Read More
July 29, 2016 - Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage
Read More

Upcoming Events

There are currently no events scheduled.

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$8.95
Change (%) Stock is Down 0.04 (0.00%)
Volume6,303
Data as of August 23, 2016 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR ContactsDownload Financial Tear Sheet Financial Tear Sheet